FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2297-2307 November 30, 2006 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by McCullough, A. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus.

Methods We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy–confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([¹⁴C]glucose given with the oral glucose load and [³H]glucose given by intravenous infusion).

Results Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed.

Conclusions In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .)

Source Information

From the University of Texas Health Science Center at San Antonio (R. Belfort, K.B., J.F., J.H., B.B., A.G., F.T., R. Berria, J.Z.M., S.D., R.H., R.D., G.A.B., S.S., K.C.); Brooke Army Medical Center (S.A.H., J.P., C.F.); and Audie L. Murphy Division, South Texas Veterans Health Care System (C.D., J.F., F.T., R.D., S.S., K.C.) — all in San Antonio, TX; and the Institute of Clinical Physiology, National Research Council, Pisa, Italy (A.G.).

Address reprint requests to Dr. Cusi at the University of Texas Health Science Center at San Antonio, Diabetes Division, Rm. 3.380S, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, or at cusi{at}uthscsa.edu.

Full Text of this Article

Related Letters:

Pioglitazone in Nonalcoholic Steatohepatitis
Targher G., Chavez-Tapia N. C., Barrientos-Gutierrez T., Uribe M., Ota T., Takamura T., Kaneko S., Harrison S. A., Schenker S., Cusi K.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:1067-1069, Mar 8, 2007. Correspondence

This article has been cited by other articles:

• Deivanayagam, S., Mohammed, B S., Vitola, B. E, Naguib, G. H, Keshen, T. H, Kirk, E. P, Klein, S. (2008). Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am. J. Clin. Nutr. 88: 257-262 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Approaches to Treatment of Type 2 Diabetes. Diabetes Care 31: 1697-1703 [Full Text]  
• Targher, G., Chonchol, M., Bertolini, L., Rodella, S., Zenari, L., Lippi, G., Franchini, M., Zoppini, G., Muggeo, M. (2008). Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease. J. Am. Soc. Nephrol. 19: 1564-1570 [Abstract] [Full Text]  
• Rigamonti, E., Chinetti-Gbaguidi, G., Staels, B. (2008). Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men. Arterioscler. Thromb. Vasc. Bio. 28: 1050-1059 [Abstract] [Full Text]  
• Clemenz, M., Frost, N., Schupp, M., Caron, S., Foryst-Ludwig, A., Bohm, C., Hartge, M., Gust, R., Staels, B., Unger, T., Kintscher, U. (2008). Liver-Specific Peroxisome Proliferator-Activated Receptor {alpha} Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan. Diabetes 57: 1405-1413 [Abstract] [Full Text]  
• Valenti, L., Rametta, R., Dongiovanni, P., Maggioni, M., Ludovica Fracanzani, A., Zappa, M., Lattuada, E., Roviaro, G., Fargion, S. (2008). Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes 57: 1355-1362 [Abstract] [Full Text]  
• Stefanovic-Racic, M., Perdomo, G., Mantell, B. S., Sipula, I. J., Brown, N. F., O'Doherty, R. M. (2008). A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am. J. Physiol. Endocrinol. Metab. 294: E969-E977 [Abstract] [Full Text]  
• El-Naggar, M. H., Helmy, A., Moawad, M., Al-Omary, M., Al-Kadhi, Y., Habib, B. (2008). Late-Onset Rosiglitazone-Associated Acute Liver Failure in a Patient with Hodgkin's Lymphoma. The Annals of Pharmacotherapy 42: 713-718 [Abstract] [Full Text]  
• Fujimoto, M., Tsuneyama, K., Kainuma, M., Sekiya, N., Goto, H., Takano, Y., Terasawa, K., Selmi, C., Gershwin, M. E., Shimada, Y. (2008). Evidence-Based Efficacy of Kampo Formulas in a Model of Non Alcoholic Fatty Liver. Exp. Biol. Med. 233: 328-337 [Abstract] [Full Text]  
• Cassiman, D., Jaeken, J. (2008). NASH may be trash. Gut 57: 141-144 [Full Text]  
• Friedman, S. L. (2008). Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiol. Rev. 88: 125-172 [Abstract] [Full Text]  
• Juurinen, L., Kotronen, A., Graner, M., Yki-Jarvinen, H. (2008). Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses. J. Clin. Endocrinol. Metab. 93: 118-124 [Abstract] [Full Text]  
• Kotronen, A., Yki-Jarvinen, H. (2008). Fatty Liver: A Novel Component of the Metabolic Syndrome. Arterioscler. Thromb. Vasc. Bio. 28: 27-38 [Abstract] [Full Text]  
• Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Corner, A., Bergholm, R., Yki-Jarvinen, H. (2008). Liver Fat Is Increased in Type 2 Diabetic Patients and Underestimated by Serum Alanine Aminotransferase Compared With Equally Obese Nondiabetic Subjects. Diabetes Care 31: 165-169 [Abstract] [Full Text]  
• Harrison, S. A, Day, C. P. (2007). Benefits of lifestyle modification in NAFLD. Gut 56: 1760-1769 [Full Text]  
• Gustafson, B., Hammarstedt, A., Andersson, C. X., Smith, U. (2007). Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 27: 2276-2283 [Abstract] [Full Text]  
• Barreyro, F. J., Kobayashi, S., Bronk, S. F., Werneburg, N. W., Malhi, H., Gores, G. J. (2007). Transcriptional Regulation of Bim by FoxO3A Mediates Hepatocyte Lipoapoptosis. J. Biol. Chem. 282: 27141-27154 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2007). Nonalcoholic Fatty Liver Disease and Insulin Resistance in Youth. Diabetes Care 30: 1663-1669 [Abstract] [Full Text]  
• Cusi, K., Kashyap, S., Gastaldelli, A., Bajaj, M., Cersosimo, E. (2007). Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292: E1775-E1781 [Abstract] [Full Text]  
• Targher, G., Chavez-Tapia, N. C., Barrientos-Gutierrez, T., Uribe, M., Ota, T., Takamura, T., Kaneko, S., Harrison, S. A., Schenker, S., Cusi, K. (2007). Pioglitazone in Nonalcoholic Steatohepatitis. NEJM 356: 1067-1069 [Full Text]  
• (2006). Pioglitazone for Nonalcoholic Steatohepatitis. JWatch General 2006: 3-3 [Full Text]  
• McCullough, A. J. (2006). Thiazolidinediones for Nonalcoholic Steatohepatitis -- Promising but Not Ready for Prime Time. NEJM 355: 2361-2363 [Full Text]  
• (2006). Pioglitazone for Treating Patients with Nonalcoholic Steatohepatitis. JWatch Gastroenterology 2006: 1-1 [Full Text]